Showing 441 - 460 results of 65,058 for search '(( 5 ((((nm decrease) OR (we decrease))) OR (a decrease)) ) OR ( 5 wt decrease ))', query time: 1.01s Refine Results
  1. 441
  2. 442

    PSG-specific <i>Fzr</i> mutation decreases the expression of silk protein genes. by Wenliang Qian (639395)

    Published 2023
    “…For the significance test: *<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001 versus the control. Scale bar, 1cm. WT, wild type. L5D3, the third day of the fifth larval instar; L5D5, the fifth day of the fifth larval instar; W0, just wandering.…”
  3. 443
  4. 444
  5. 445
  6. 446
  7. 447
  8. 448
  9. 449
  10. 450

    Prey establishment and decrease in inter-population contacts protects T6SS sensitive lineages. by Marta Rudzite (15991136)

    Published 2023
    “…Mixed bacterial colonies of WT, Δ<i>rsmA</i>, Δ<i>retS</i>, and Δ<i>rsmA</i>Δ<i>rsmN</i> strains in different columns. …”
  11. 451
  12. 452
  13. 453
  14. 454
  15. 455
  16. 456
  17. 457
  18. 458

    Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  19. 459

    Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  20. 460

    Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”